Welcome to our dedicated page for ISO news (Ticker: ISO), a resource for investors and traders seeking the latest updates and insights on ISO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ISO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ISO's position in the market.
Berkeley Lights, Inc. has completed its acquisition of IsoPlexis Corporation, leading to the formation of PhenomeX. Trading under the ticker CELL, this newly merged entity aims to be a leader in life sciences solutions. The merger is expected to deliver $70 million in cost synergies and boost profitability as it targets a growing market for functional cell biology. In 2022, the combined revenue was approximately $95 million, with a significant installed base of instruments in major pharmaceutical companies and cancer centers. Share distribution post-merger shows Berkeley Lights shareholders owning roughly 75.2% of PhenomeX.
IsoPlexis Corporation (NASDAQ: ISO) reported preliminary unaudited revenue for 2022, expected between $16.6 million and $16.8 million, reflecting a decrease of 3% to 4% from $17.3 million in 2021. The fourth quarter performance fell short of expectations due to delayed customer orders and reduced consumable sales amid ongoing macroeconomic challenges. However, the company grew its customer base and announced plans to merge with Berkeley Lights to enhance future operations.
Berkeley Lights has announced its acquisition of IsoPlexis in an all-stock deal valued at $57.8 million. This strategic merger, resulting in the formation of PhenomeX, aims to create a leading functional cell biology company. IsoPlexis shareholders will receive 0.612 Berkeley Lights shares per IsoPlexis share. The merger is projected to yield approximately $70 million in annual cost synergies by 2024, accelerating the timeline to profitability. The transaction is expected to close in Q1 2023, subject to shareholder approval.
Berkeley Lights (Nasdaq: BLI) has announced a definitive agreement to acquire IsoPlexis (Nasdaq: ISO) in an all-stock transaction valued at $57.8 million. The merger aims to create PhenomeX, focusing on functional cell biology research tools. IsoPlexis shareholders will receive 0.612 shares of Berkeley Lights stock for each IsoPlexis share held. The combined entity expects $70 million in annual cost synergies by 2024, driving profitability and earlier breakeven at $150 million in revenue. The transaction is set to close in early 2023, subject to shareholder approvals.
IsoPlexis Corporation (Nasdaq: ISO) reported financial results for Q3 2022, achieving $4.5 million in revenue, a 7% increase from Q3 2021. Key highlights included selling 23 new instruments, reducing operating expenses by 27% from the prior quarter, and successfully launching partnerships for multi-site cancer studies. Gross margin improved to 50%, while net loss narrowed to $18.5 million, down from $20.2 million in Q3 2021. The company projects a 11%-15% revenue growth for the full year 2022.
IsoPlexis Corporation (Nasdaq: ISO) announced its participation in two upcoming investor conferences focused on health and diagnostics. The first event is the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 17 at 1:00 p.m. ET, featuring a Multi-Omics Panel. The second event is the Evercore ISI HealthCONx Conference, held virtually on December 1 at 12:10 p.m. ET, including a fireside chat. A webcast of the latter will be accessible on the company's website.
IsoPlexis Corporation (Nasdaq: ISO) will report its third-quarter 2022 financial results on November 10, 2022, before market open. A conference call will follow at 5:30 a.m. PT / 8:30 a.m. ET. The company's platforms provide critical insights into immune cell behavior, aiding in understanding disease progression and treatment efficacy. IsoPlexis has been recognized for innovation by prominent organizations and is utilized by major pharmaceutical companies and leading cancer centers globally.
IsoPlexis Corporation (Nasdaq: ISO) announced initial data from its CodePlex platform published in Scientific Reports, conducted by the Shanghai Institute of Hematology. The study explored the impact of IL-7 secretion on CD19 CAR-T cells, indicating improved anti-tumor responses. The establishment of a regional headquarters in Shanghai enhances IsoPlexis' support for customers in the APAC region. The CodePlex platform is noted for its automation capabilities, broadening its appeal to researchers. Further updates regarding CodePlex are anticipated in the upcoming year.
IsoPlexis (NASDAQ: ISO) has partnered with MediMergent and The Center for Cancer and Blood Disorders (CCBD) to conduct a significant study on immuno-compromised cancer patients. This study, titled 'Real World Evaluation of the Effectiveness of AZD7442 for Prevention of COVID-19 Infection,' will utilize IsoPlexis’ single-cell proteomics technology to assess immune cell functionality against COVID-19 breakthrough infections. The collaboration aims to enhance understanding of immune responses in high-risk patients, contributing valuable data to the ongoing COVID-19 pandemic response.
IsoPlexis Corporation (Nasdaq: ISO) announced participation in the Morgan Stanley Global Healthcare Conference on September 12, 2022. The management will engage in a fireside chat at 4:50 p.m. ET, which will also be available as a live and archived webcast on the company’s website. IsoPlexis aims to empower labs by enhancing the understanding of multi-functional immune cells, aiding in the prediction of disease progression and treatment responses. Recognized for its innovative platform, IsoPlexis serves top pharmaceutical firms and leading cancer centers globally.
FAQ
What is the market cap of ISO (ISO)?
